NewsBenzingaAgomab Therapeutics、重症クローン病患者におけるontunisertibを評価する第2a相STENOVA試験の48週間OLEパートの結果を発表;最大60週間の投与を通じて良好な安全性および忍容性プロファイルを維持;FSCD関連イベントの年換算発生率は3%と低値 Agomab Therapeutics、重症クローン病患者におけるontunisertibを評価する第2a相STENOVA試験の48週間OLEパートの結果を発表;最大60週間の投与を通じて良好な安全性および忍容性プロファイルを維持;FSCD関連イベントの年換算発生率は3%と低値 Benzinga 2026.10.01 10:38 (GMT+0) Open on Benzinga Other news If You Invested $1000 In SPDR Gold MiniShares Trust Stock 5 Years Ago, You Would Have This Much Today $100 Invested In Caterpillar 10 Years Ago Would Be Worth This Much Today Here’s How Much You Would Have Made Owning Royal Caribbean Group Stock In The Last 15 Years Bitcoin Faces Historic Capitulation Levels: Can $62,000 Support Hold? $1000 Invested In Teck Resources 5 Years Ago Would Be Worth This Much Today 'Microsoft Executive Says Nvidia Drama Could Boost Rival Chips'- Bloomberg
If You Invested $1000 In SPDR Gold MiniShares Trust Stock 5 Years Ago, You Would Have This Much Today